SAN DIEGO , Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
Target Selector™ kits are research-use-only (RUO) and designed to enable laboratories around the world to leverage Biocept's patented assay technology to perform cutting-edge liquid biopsy testing SAN DIEGO , Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc.
Peer-reviewed article in journal, Clinics in Oncology, further supports the clinical utility of Biocept's Target Selector™ platform to aid physicians in the selection of targeted therapy for patients with lung cancer SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Biocept, Inc.
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC ), a leading commercial provider of liquid biopsy solutions, announces that it has entered into an agreement with Agiomix FZ-LLC ("Agiomix"), a provider of genomics sample and bioinformatics services to customers around the
SAN DIEGO , Feb. 8, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock and warrants to purchase up to
Focus on new market segments and strategies to drive growth SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients
Saint John's and John Wayne Cancer Institute to validate use of cerebrospinal fluid with the Company's Target Selector™ assay platform in patients with known or suspected brain metastases SAN DIEGO , Feb. 27, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of
Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer SAN DIEGO , March 4, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Proprietary platform enables local pathologists to participate in liquid biopsy testing with new capabilities to evaluate circulating tumor cells (CTCs) and expanded menu of biomarkers SAN DIEGO , March 13, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid
SAN DIEGO , March 15, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
